

# William Blair 42<sup>nd</sup> Annual Growth Stock Conference

Our Mission: To deliver a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and services.

June 2022



















# FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events; in some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could" and similar expressions. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the impact of COVID-19 on our business and the global economy; our ability to successfully grow our business through acquisitions; our dependency on a limited number of customers; our ability to implement our growth strategy effectively; disruptions in our manufacturing and distribution chains; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; our ability to introduce new products and improve existing products; our ability to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; our ability to sustain profitability and the risks set forth under the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings from time to time with the Securities and Exchange Commission.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.

This presentation includes certain non-GAAP financial measures, including adjusted gross profit, adjusted G&A, adjusted net income and Adjusted EBITDA. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please refer to the Appendix of this presentation for a reconciliation of these measures to net income, the most directly comparable financial measure prepared in accordance with U.S. GAAP.





# **CONTENTS**

- BUSINESS OVERVIEW
- PRODUCTS SEGMENT HIGHLIGHTS
- SERVICES SEGMENT HIGHLIGHTS
- APPENDIX







# **BUSINESS OVERVIEW**



**UNIQUE ANIMAL HEALTH PLATFORM** 



**CENTERS** ~ 1.2 M PETS **SERVED IN 2021 MULTI-YEAR COMPANIES** 6

**MULTI-CHANNEL CUSTOMER** LARGEST OTC **EXECUTION ANIMAL HEALTH PORTFOLIO WITH OVER 1,000 ITEMS** 

> COMPLETE **SERVICE PROVIDER**

 DISTRIBUTION & LOGISTICS

SALES

MANUFACTURING

OPERATIONS

SERVICE

#### **PET Rx**

24 HOUR DELIVERY TO **CONTRACTS WITH** LARGEST ANIMAL **HEALTH PHARMA** 

60,000+ PHARMACIES DOMINANT RETAIL MARKET SHARE





### PETIQ IS THE ONLY ANIMAL HEALTH COMPANY 100% PARTNERED WITH USA RETAILERS



#### **Animal Health Products**

- \$843 M LTM 1Q22 PRODUCT SALES
- 1,000+ PETIQ BRANDED ITEMS MANUFACTURED
- 500+ DISTRIBUTED MEDICATIONS
- 40+ RETAIL PARTNERS
- 60,000+ POINTS OF DISTRIBUTION
- LEADER IN ONLINE AND DTC ANIMAL HEALTH SALES VOLUME










#### **Veterinary Services**

- CONVENIENT AND AFFORDABLE VET CARE
- ~ 3,000 CLINIC LOCATIONS
- ~ 1.2 M PETS SERVED IN 2021
- 2,500+ VETERINARIANS
- MOBILE & FIXED CLINIC LOCATIONS
- 35 REGIONAL OFFICES SERVING 42 STATES




#### **OUR PRODUCTS REACH PET PARENTS WHERE THEY CHOOSE TO PURCHASE**



VETERINARY SERVICES • PHARMACEUTICALS • PET PRODUCTS




## **RECORD FINANCIAL PERFORMANCE**



#### **GROWING SIGNIFICANTLY FASTER THAN THE ANIMAL HEALTH INDUSTRY'S 7% CAGR**



### PRODUCT SEGMENT CONSISTENT DRIVER OF ANNUAL GROWTH



CHANGE IN BRANDED PRODUCT SALES FROM 20% IN 2018 TO A PROJECTED 32% IN 2022 WITH ~55% MARGIN





# **PRODUCTS SEGMENT**



#### LARGEST PORTFOLIO OF OTC PET HEALTH & WELLNESS PRODUCTS = COMPETITIVE ADVANTAGE

# **RX Pet Meds Ne**xGard **Ne**xGard NexGard Heartgard > Heartgard > Heartgard 💝







### Treats





Predictable revenue streams with significant new innovation and sales and profit contribution



## STATE OF THE ART OTC MANUFACTURING & DISTRIBUTION FACILITIES

- 900,000+ Square Feet of Our Own Facilities
- Over 1,200 Items Manufactured
  - Flea & Tick
  - Health & Wellness
  - Prescription Drug
  - Treats
- EPA/FDA Licensed
- SQF Certified



CAPSTAR













1375 N. Mountain Springs Pkwy Springville, Utah 84663 sqft - 240,000





530 Fentress Blvd Daytona Beach, Florida 32114 sqft - 142,900





3601 E Plano Parkway, Suite 150 Plano, Texas 75074 **sqft - 60,000** 






10077 S 134th St Omaha, Nebraska 6813 **sqft - 462,000** 





## **EXPECT CONTINUED STRONG CONTRIBUTION FROM PETIQ'S BRANDS**



PETIQ'S BRAND MARGIN OF ~55% IS SIGNIFICANTLY HIGHER THAN DISTRIBUTED PRODUCT MARGIN



### **CONTINUED GROWTH OF PRODUCT SEGMENT**

#### **SOURCES OF GROWTH IN 2022 AND BEYOND**

#### **CATEGORY**

**Increasing Household Penetration of Pets** 

**Premiumization / Humanization** 

**Increasing Pet Population** 

**Channel Migration From Vet** 



#### **NEW ITEM INNOVATION**

**Super Premium Flea & Tick** 

**Cutting Edge Supplements** 

**Distribution Pipeline** 

**Direct to Consumer Initiatives** 















# **SERVICES SEGMENT**



### VETERINARY SERVICES TOTAL PETS SERVED IN 2021: ~1.2 MILLION

#### 1Q22 HIGHEST PETS PER CLINIC AND DOLLARS PER CLINIC IN THE HISTORY OF THE COMPANY

#### **COMMUNITY CLINICS: MOBILE MODEL**









#### WELLNESS CENTERS: PHYSICAL LOCATIONS








33% of pet parents strongly agree and 35% of pet parents somewhat agree they are concerned about the affordability of routine healthcare for their pet<sup>1</sup>. 55% of pet parents come to PetIQ for affordable services, 41% for no appointment needed<sup>2</sup>



## **NATIONWIDE INFRASTRUCTURE ACROSS 42 STATES**





Where We Operate – CURRENT FOOTPRINT

## **OPERATING VETERINARY CLINICS NEAR 90% OF THE U.S. POPULATION**



# **COMPELLING MARKET POSITION**

Service Provider	Footprint Coverage (States)	Multiple Partnerships	Top 20 US Pet Retailer	Non-Pet Retailers	Mobile Clinics	Wellness Centers
PETIQ	42	✓	11	<b>√</b>	<b>√</b>	<b>✓</b>
BANFIELD PET HOSPITALS	42	X	1	X	X	<b>√</b>
NATIONAL VETERINARY ASSOCIATES (NVA)	43	X	0	X	x	✓
VCA ANIMAL HOSPITALS	46	X	0	X	X	✓
VETCO ( PETCO )	43	X	1	X	✓	✓
SHOTVET	38	✓	2	✓	✓	X
THRIVE	36	X	0	X	X	✓
GOOD NEIGHBOR VET	2	✓	0	✓	✓	X
EZ VET	2	✓	1	X	X	<b>✓</b>
PETSTOP	2	✓	0	✓	✓	X
ESSENTIALS PETCARE	3	X	1	<b>✓</b>	X	<b>✓</b>
VACCINATION STATION	1	<b>√</b>	0	✓	✓	х



### PETIQ OFFERS VETERINARIANS THE ABILITY TO PRACTICE LOW-STRESS MEDICINE

Over 40% of veterinarians who graduated in the last 10 years are thinking of leaving the profession due to mental health (33%) and work-life balance (27%) as their top reasons<sup>1</sup>

BREAKING DOWN
THE BARRIERS to
Preventative Pet Health

**PET PRODUCTS** 

**VETERINARY SERVICES** 

MANUFACTURING




OUR DIFFERENCE
FIVE-STAR
Preventative Veterinary Care



- Best-Practice
  Preventative Care
- Veterinarian Expertise
- National Footprint Local Focus
- Affordable & Convenient
- The PetIQ Promise Starts With You

PetIQ's unique, nation-wide, clinic operations offers veterinary professionals work-life balance and the ability to provide preventative care for pets in an affordable and convenient setting







**PET PARENTS** 

# **Creating Value Through Smarter Pet Health**











**MANUFACTURERS** 







# **APPENDIX**



# **ADJUSTED EBITDA RECONCILIATION**

	THREE MONTHS ENDED			YEAR ENDED <sup>1</sup>		
\$ IN MILLIONS	3/31/2022	3/31/2021	12/31/2021	12/31/2020	12/31/2019	
NET INCOME	3,160	2,386	(16,383)	(85,727)	(14,302)	
PLUS:						
TAX EXPENSE (BENEFIT)	121	75	3,869	60,413	(3,309)	
DEPRECIATION	3,682	3,131	14,366	12,082	9,139	
AMORTIZATION	4,523	8,428	22,336	12,815	5,994	
INTEREST	6,121	4,870	24,696	22,807	14,495	
EBITDA	17,607	18,890	48,884	22,390	12,017	
ACQUISITION COSTS	_	6	92	2,620	6,147	
STOCK BASED COMPENSATION EXPENSE	3,823	2,122	9,428	9,170	7,355	
PURCHASE ACCOUNTING ADJ TO INVENTORY	_	_	_	_	4,805	
LITIGATION EXPENSES	2,661	243	4,105	1,006	529	
NON SAME-STORE NET (INCOME) LOSS	7,165	5,648	23,159	16,354	12,232	
FAIR VALUE ADJ OF CONTINGENT NOTE	_	_	_	_	7,320	
INTEGRATION COSTS AND COSTS OF DISCONTINUED CLINICS	339	(48)	(142)	9,776	3,788	
SKU RATIONALIZATION	_	_	_	_	6,482	
COVID-19 RELATED COSTS	_	_	_	6,476	_	
CFO TRANSITION	_	_	928	_	_	
LOSS ON EXTINGUISHMENT AND RELATED COSTS	_	_	6,438	_	_	
ADJUSTED EBITDA	31,595	26,861	92,892	67,792	60,675	

 $<sup>^{1}</sup>$  – For years prior to 2019, please refer to previously filed 10-K's and other public filings